Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)

International Journal of Cancer

Volumn 104, Issue 1, 2003, Pages 121-129

  Grant, Derrick S ^a   Williams, Torian L ^b   Zahaczewsky, Michael ^a   Dicker, Adam P ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Anti tumor; Docetaxel; Dosing; Paclitaxel; Taxols

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; DOCETAXEL; PACLITAXEL;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL; CANCER GROWTH; CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SOLID TUMOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; APOPTOSIS; CAPILLARIES; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOTHELIUM, VASCULAR; FIBROSARCOMA; GLIOBLASTOMA; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; RATS; TAXOIDS; TUMOR CELLS, CULTURED; UMBILICAL VEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037430246     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10907     Document Type: Article

References (52)

1. Balsari A, Maier JA, Colnaghi MI, Menard S. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels and serum angiogenic activity in patients with breast carcinoma. Lab Invest 1999;79:897-902.
2. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032: 89-108.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
4. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
6. Grant DS, Kibbey MC, Kinsella JL, Cid MC, Kleinman HK. The role of basement membrane in angiogenesis and tumor growth. Pathol Res Pract 1994;190:854-63.
7. Belani C, Lynch T. Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol 2001;28:10-4.
8. Burris HA III. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28:38-44.
9. Calderoni A, Cerny T. Taxanes in lung cancer: a review with focus on the European experience. Crit Rev Oncol Hematol 2001;38:105-27.
10. Choy H. Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001;37:237-47.
11. Hortobagyi GN. Recent progress in the clinical development of docetaxel (Taxotere). 1999;26:32-6.
12. Rose WC, Fairchild C, Lee FY. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001;47:97-105.
13. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31-6.
14. Arioka H, Saijo N. [Microtubules and antineoplastic drugs]. Gan To Kagaku Ryoho 1994;21:583-90.
15. Choy H, Akerley W, Devore RF III. Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1999;26:36-43.
16. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002;38:223-30.
17. Herscher LL, Cook J. Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol 1999;11:183-6.
18. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9:12-26.
19. Dicker AP, Williams TL, Iliakis G, Grant DS. Targeting angiogenic processes by combination low dose paclitaxel and radiation therapy. Am J Clin Oncol 2002 (in press).
20. Mason KA, Kishi K, Hunter N, Buchmiller L, Akimoto T, Komaki R, Milas L. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-8.
21. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radio response in vivo. Clin Cancer Res 1997;3: 2431-8.
22. Milross CG, Mason KA, Hunter NR, Terry NH, Patel N, Harada S, Jibu T, Seong J, Milas L. Enhanced radio response of paclitaxel-sensitive and -resistant tumours in vivo. Eur J Cancer 1997;33:1299-308.
23. Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C. Concurrent paclitaxel and radiation therapy for solid tumors. Cancer Control 1996;3:310-8.
24. Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology 1999;13:23-38.
25. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, von Hoff DD. Investigation of Taxol as a potential radiation sensitizer. Cancer 1993;71:3774- 8.
26. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61:3369-72.
27. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK. Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 1989;58:933-43.
28. Grant DS, Kinsella JL, Kibbey MC, Laflamme S, Burbelo PD, Goldstein AL, Kleinman HK. Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J Cell Sci 1995;108:3685-94.
29. Burd R, Wachsberger PR, Biaglow JE, Wahl ML, Lee I, Leeper DB. Absence of Crabtree effect in human melanoma cells adapted to growth at low pH: reversal by respiratory inhibitors. Cancer Res 2001;61:5630-5.
30. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
31. Grant DS, Kinsella JL, Fridman R, Auerbach R, Piasecki BA, Yamada Y, Zain M, Kleinman HK. Interaction of endothelial cells with a laminin A chain peptide (SIKVAV) in vitro and induction of angiogenic behavior in vivo. J Cell Physiol 1992;153:614-25.
32. Grant DS, Lelkes PI, Fukuda K, Kleinman HK. Intracellular mechanisms involved in basement membrane induced blood vessel differentiation in vitro. In Vitro Cell Dev Biol 1991;27A:327-36.
33. Nicosia RF, Madri JA. The microvascular extracellular matrix. Developmental changes during angiogenesis in the aortic ring-plasma clot model. Am J Pathol 1987;128:78-90.
34. Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. 1990;63:115-22.
35. Knudsen TB. Cellular techniques for teratological cell death. In: Daston GP, ed. Molecular and cellular methods in developmental toxicology. Boca Raton: CRC Press, 1997.
36. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;19:646-62.
37. Bunn PA Jr. Triplet combination chemotherapy and targeted therapy regimens. Oncology 2001;15:26-32.
38. Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 2001;28:22-7.
39. Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis C, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N, Georgoulias V. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001;32:179-87.
40. Hoff DDV. Taxoids: same roots, different drugs. Semin Oncol 1997; 24:S13.3-10.
41. Leahy M, Howell A. Docetaxel. Br J Hosp Med 1997;57:141-4.
42. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
43. Eckardt JR. Antitumor activity of docetaxel. Am J Health Syst Pharm 1997;54:2-6.
44. Hortobagyi GN. An expanding role for docetaxel. Semin Oncol 1998; 25:1-3.
45. Schimming R, Hunter NR, Mason KA. Milas L. [Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (Taxotere)]. Mund Kiefer Gesichtschir 1999;3:210-2.
46. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
47. Wang G-S, Yang K-Y, Perng R-P. Life-threatening hypersensitivity pneumonitis induced by docetaxel (Taxotere). Brit J Cancer 2001;85: 1247-50.
48. Yasuda S, Noguchi T, Gohda M, Arai T, Tsutsui N, Nakayama Y, Matsuda T, Nonogi H. Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model. Cardiovasc Res 2002;53: 481-6.
49. Ioannis AA, Kwock R, Avramis V. Taxotere adn vincristine inhibit the secretion of the angiogenesis-inducing vascular endothelial growth factor (vegf) by wild-type adn drug-resistant human leukemia T-cell lines. Anticancer Res 2001;21:2281-6.
50. Kurdoglu B, Cheong N, Guan J, Corn BW, Curran WJ Jr, Iliakis G. Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines. Clin Cancer Res 1999;5:2-7.
51. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999:14:31-6.
52. Wood JM. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Medicina 2000;60(Suppl): 41-7.